Drug Program | Target/Delivery | Therapeutic Area | Discovery | IND enabling | Phase 1a | Phase 1b | ||
---|---|---|---|---|---|---|---|---|
Targeted Protein Degradation | ||||||||
NX-2127 Degrader | BTK + IKZF (Oral) | B-cell malignancies |
| |||||
NX-5948 Degrader | BTK (Oral) | B-cell malignancies |
| |||||
NX-0479 / GS-6791 Degrader | IRAK4 (Oral) | Rheumatoid arthritis and other inflammatory diseases |
![]() | |||||
Drug Program | Target/Delivery | Therapeutic Area | Discovery | IND enabling | Phase 1a | Phase 1b | ||
Targeted Protein Elevation | ||||||||
NX-1607 Inhibitor | CBL-B (Oral) | Immuno-oncology |
| |||||
Drug Program | Target/Delivery | Therapeutic Area | Discovery | IND enabling | Phase 1a | Phase 1b | ||
Discovery Pipeline | ||||||||
Wholly Owned | 5 targets | Undisclosed |
| |||||
Gilead Sciences | 4 Targets | Undisclosed |
| |||||
Sanofi | 5 Targets | Undisclosed |
|
Targeted Protein Degradation | NX-2127 DegraderBTK + IKZF (Oral) - B-cell malignancies |
Preclinical IND-Enabling Phase 1a Phase 1b |
|
NX-5948 DegraderBTK (Oral) - B-cell malignancies |
Preclinical IND-Enabling Phase 1a Phase 1b |
|
NX-0479 / GS-6791 DegraderIRAK4 (Oral) - Rheumatoid arthritis and other inflammatory diseases |
Preclinical IND-Enabling Phase 1a Phase 1b |
![]() |
Targeted Protein Elevation | NX-1607 InhibitorCBL-B (Oral) - Immuno-oncology |
Preclinical IND-Enabling Phase 1a Phase 1b |
|
Discovery Pipeline | Wholly Owned 5 targets - Undisclosed |
Preclinical IND-Enabling Phase 1a Phase 1b |
|
Gilead Sciences4 Targets - Undisclosed |
Preclinical IND-Enabling Phase 1a Phase 1b |
|
Sanofi5 Targets - Undisclosed |
Preclinical IND-Enabling Phase 1a Phase 1b |
|